Global Innovation Index 2020: Switzerland is the world’s most-innovative country, but who will finance innovation?

Wednesday, September 2, 2020 @ 12:00 am

The 2020 edition of the GII ranks the innovation performance of 131 economies around the world relying on around 80 indicators. These indicators capture the institutional environment for innovation, the education system, research and development activity, the infrastructure for innovation and different forms of knowledge, technology and creative outputs.

The World Intellectual Property Organization released the Global Innovation Index (GII) 2020. As the world is struggling to cope with the implications of the COVID-19 crisis, there is a true risk that innovation expenditures and the means to finance entrepreneurial ventures will spiral downwards as global economic output declines. The impact of this shortage in innovation finance will be uneven, with the negative effects felt more heavily by young firms, by R&D-intensive firms, and start-ups in developing economies.

According to the GII 2020 innovation ranking, Switzerland is the world’s most-innovative country followed by Sweden, the United States of America, the United Kingdom, and the Netherlands.

Key Findings of the GII 2020 - Watch the 5 minute video and read the Global Innovation Index Report 2020

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Vandria becoming clinical stage company: First clinical trial for neurodegenerative disorders

Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today announces that the first subjects have been dosed in its first-in-human clinical trial of its lead Central Nervous System (CNS) compound VNA-318. Readout of this combined single and multiple ascending dose trial is expected in the summer of 2025.
December 18, 2024

BioCopy's CEO Matthias Wiedenfels among Germany's biotech pioneers of the coming decade

BioCopy CEO Matthias Wiedenfels honored as winner of "Germany's 30 by 2030" award.
December 17, 2024

The co-founders of AlphaMol are ranked as the "top 2% scientists" in the world

December 16, 2024

Porton Pharma Solutions: Collaboration with Aojin Life Sciences in China and USA

December 13, 2024

MedScienceSwiss: Combatting antibiotic-resistant bacteria with “Plan B”

MedScienceSwiss is developing a non-pharmaceutical therapy for the treatment of antibiotic-resistant bacteria. The goal: to significantly reduce the number of deaths in hospitals due to nosocomial (difficult-to-treat) infections. The technology is not only intended to serve as an alternative to the current plan A (antibiotics), but also to function as a general approach to the treatment of resista
December 3, 2024